Sun Pharma Rises as TARO Acquires Antibe Therapeutics for $4.5M

Sun Pharmaceutical Industries subsidiary  TARO Pharmaceuticals Inc. has completed the 100% acquisition of Antibe Therapeutics Inc., a Canadian company for $4.5 million.  After this announcement, the stock price jumped by 1.14% to ?1,725.55.

The purchase strengthens Sun Pharma's international foothold in specialty and pain management medication. Being the largest drug manufacturer in India, Sun Pharma is expanding its footprint in the world generic and specialty medicine markets.

After a good Q3 FY25 when consolidated net profit rose by 15.04% to ?2,903.38 crore and revenue from operations increased 10.46% to ?13,675.46 crore, Sun Pharma is working on expanding its product pipeline.

Sun Pharma recently has launched new formulations in dermatology, ophthalmology, and oncology in line with its R&D investment. It's also pushing its biologics portfolio with newer therapies for autoimmune diseases and diseases that badly affect the skin.

Also, the firm is progressing with late-stage clinical trials for new medicines for psoriasis and atopic dermatitis. Specialty drug Ilumya (tildrakizumab) is receiving good acceptance and showing decent traction especially in US and emerging markets.

By focusing on specialty drugs and R&D and expanding globally, Sun Pharma is among the pharmaceutical innovators seeking to sustain growth amid an intense competition in the healthcare market.